1. Copyright © 2003 American Medical Association. All rights reserved.
From: HuMax-CD4A Fully Human Monoclonal Anti-CD4 Antibody for the Treatment of Psoriasis Vulgaris
Arch Dermatol. 2003;139(11): doi: /archderm
Figure Legend:
Mean percentage decrease in Psoriasis Area and Severity Index (PASI) during treatment with a fully human monoclonal antibody against the CD4 molecule, HuMax-CD4 (Genmab A/S, Copenhagen, Denmark), or placebo and 4 weeks of follow-up. Data are for all 85 patients included, with the last-observation-carried-forward principle applied. Arrowheads represent drug administration.
Date of download: 10/18/2017
Copyright © 2003 American Medical Association. All rights reserved.

2. Copyright © 2003 American Medical Association. All rights reserved.
From: HuMax-CD4A Fully Human Monoclonal Anti-CD4 Antibody for the Treatment of Psoriasis Vulgaris
Arch Dermatol. 2003;139(11): doi: /archderm
Figure Legend:
Proportion of patients with improvement ip Psoriasis Area and Severity Index (PASI) of 25% (PASI25) and 50% (PASI50) or more at week 7, the primary end point.
Date of download: 10/18/2017
Copyright © 2003 American Medical Association. All rights reserved.

3. Copyright © 2003 American Medical Association. All rights reserved.
From: HuMax-CD4A Fully Human Monoclonal Anti-CD4 Antibody for the Treatment of Psoriasis Vulgaris
Arch Dermatol. 2003;139(11): doi: /archderm
Figure Legend:
Improvement in psoriasis from baseline (A) to week 7 (B), week 15 (C), and week 48 (D) in a patient treated with a fully human monoclonal antibody against the CD4 molecule, HuMax-CD4 (Genmab A/S, Copenhagen, Denmark), 280 mg once a week for 4 weeks.
Date of download: 10/18/2017
Copyright © 2003 American Medical Association. All rights reserved.

4. Copyright © 2003 American Medical Association. All rights reserved.
From: HuMax-CD4A Fully Human Monoclonal Anti-CD4 Antibody for the Treatment of Psoriasis Vulgaris
Arch Dermatol. 2003;139(11): doi: /archderm
Figure Legend:
Mean peripheral blood lymphocyte counts according to treatment group. Arrowheads represent drug administration.
Date of download: 10/18/2017
Copyright © 2003 American Medical Association. All rights reserved.

5. Copyright © 2003 American Medical Association. All rights reserved.
From: HuMax-CD4A Fully Human Monoclonal Anti-CD4 Antibody for the Treatment of Psoriasis Vulgaris
Arch Dermatol. 2003;139(11): doi: /archderm
Figure Legend:
Mean increase in receptor saturation measured by the occupancy of the CD4 receptor during treatment and 4 weeks of follow-up. Receptor saturation at weeks 0, 1, and 2 was measured in blood sampled just before infusion of a fully human monoclonal antibody against the CD4 molecule, HuMax-CD4 (Genmab A/S, Copenhagen, Denmark).
Date of download: 10/18/2017
Copyright © 2003 American Medical Association. All rights reserved.